Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Pfizer's Adjusted Q4 Profit Rises 22% as Generic Competition Erodes Top Line

Pfizer (NYSE: PFE  ) , the world's largest research-based pharmaceutical company, delivered a mixed fourth-quarter report before the opening bell this morning, highlighting an adjusted EPS increase of 22% to $0.56 at the expense of a 2% decline in reported revenue to $13.56 billion.

On an operation basis, Pfizer's biggest drag came from its primary care and specialty care segments, where revenue declined 8% and 5%, respectively. Primary care revenue was negatively affected by ongoing patent expirations of LDL cholesterol-lowering medication Lipitor in developed markets, while its specialty care segment suffered from the end of a three-year collaboration agreement for rheumatoid arthritis medication Enbrel.

If there was one bright spot, it was Pfizer's oncology division, which saw revenue climb 26% on an operating basis due to a 126% year-over-year increase in Inlyta sales, and a 105% rise in Xalkori sales, excluding the negative effects of currency translation. Unfortunately, Pfizer's oncology division accounts for just 3.5% of total revenue.

Lower expenses were one of the reasons Pfizer was able to boost its adjusted EPS by 22% over the previous year as research and development expenses dipped $94 million, or 5%, from the year-ago quarter. However, the simple fact that Pfizer repurchased $4.6 billion worth of common stock, and $16.3 billion during the course of 2013, certainly helped its EPS rise as well since there are fewer shares now outstanding. Including one-time costs, and the fact that Pfizer recognized a sizable gain last year from the discontinuation of reporting results from its animal health division, Zoetis, which was spun off in February 2013, net income fell by 59%.

Looking ahead, Pfizer anticipates delivering $49.2 billion to $51.2 billion in revenue for the full year in 2014 -- a 2.7% decline from 2013 at the midpoint -- with an adjusted EPS forecast of $2.20 to $2.30, which is essentially flat from the adjusted $2.22 it reported in 2013. This forecast, according to commentary from Pfizer CFO Frank D'Amelio is based on the expected negative impact of $3 billion from increased generic competition and higher R&D expenses, but it should be counteracted by the anticipated repurchase of $5 billion in common stock in 2014.

Pfizer shares were up around 2% as of midday trading. 


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2812957, ~/Articles/ArticleHandler.aspx, 9/1/2015 2:30:58 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,109.36 -418.67 -2.53%
S&P 500 1,919.24 -52.94 -2.68%
NASD 4,659.96 -116.55 -2.44%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 2:15 PM
PFE $31.53 Down -0.69 -2.14%
Pfizer CAPS Rating: ****